A phase 4, open label, randomized, controlled study to assess the effect on lipid profile of switching from a stable HAART regimen of fixed dose abacavir/lamivudine (Kivexa) plus efavirenz, to once daily Atripla in adult HIV-1 infected subjects with raised cholesterol.

Trial Profile

A phase 4, open label, randomized, controlled study to assess the effect on lipid profile of switching from a stable HAART regimen of fixed dose abacavir/lamivudine (Kivexa) plus efavirenz, to once daily Atripla in adult HIV-1 infected subjects with raised cholesterol.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Efavirenz; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms ROCKET-I
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 15 Sep 2010 Results presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • 30 Jul 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
    • 30 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top